25 XP   0   0   10

Morphosys AG O.N.
Buy, Hold or Sell?

Let's analyse Morphosys together

PenkeI guess you are interested in Morphosys AG O.N.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Morphosys AG O.N.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Morphosys AG O.N.

I send you an email if I find something interesting about Morphosys AG O.N..

Quick analysis of Morphosys (30 sec.)










What can you expect buying and holding a share of Morphosys? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€1.24
Expected worth in 1 year
€-1.69
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
€-2.93
Return On Investment
-4.3%

For what price can you sell your share?

Current Price per Share
€68.45
Expected price per share
€68.00 - €
How sure are you?
50%

1. Valuation of Morphosys (5 min.)




Live pricePrice per Share (EOD)

€68.45

Intrinsic Value Per Share

€-93.27 - €7.26

Total Value Per Share

€-92.03 - €8.50

2. Growth of Morphosys (5 min.)




Is Morphosys growing?

Current yearPrevious yearGrowGrow %
How rich?$53.2m$50.3m-$20.2m-67.5%

How much money is Morphosys making?

Current yearPrevious yearGrowGrow %
Making money-$51.3m-$55.8m$4.4m8.8%
Net Profit Margin-78.8%-136.9%--

How much money comes from the company's main activities?

3. Financial Health of Morphosys (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#456 / 1001

Most Revenue
#106 / 1001

Most Profit
#905 / 1001

Most Efficient
#523 / 1001

What can you expect buying and holding a share of Morphosys? (5 min.)

Welcome investor! Morphosys's management wants to use your money to grow the business. In return you get a share of Morphosys.

What can you expect buying and holding a share of Morphosys?

First you should know what it really means to hold a share of Morphosys. And how you can make/lose money.

Speculation

The Price per Share of Morphosys is €68.45. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Morphosys.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Morphosys, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €1.24. Based on the TTM, the Book Value Change Per Share is €-0.73 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.58 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Morphosys.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps1.321.9%-1.38-2.0%-1.09-1.6%-1.24-1.8%-0.75-1.1%
Usd Book Value Change Per Share3.274.8%-0.80-1.2%-0.63-0.9%-0.64-0.9%-0.22-0.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share3.274.8%-0.80-1.2%-0.63-0.9%-0.64-0.9%-0.22-0.3%
Usd Price Per Share36.92-27.61-20.98-64.67-68.45-
Price to Earnings Ratio6.97--0.41--0.96--15.77--63.72-
Price-to-Total Gains Ratio11.28--5.87--6.10--100.76--59.15-
Price to Book Ratio27.42-12.75--6.26-5.04-5.77-
Price-to-Total Gains Ratio11.28--5.87--6.10--100.76--59.15-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share74.32301
Number of shares13
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.80-0.64
Usd Total Gains Per Share-0.80-0.64
Gains per Quarter (13 shares)-10.35-8.26
Gains per Year (13 shares)-41.41-33.05
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-41-510-33-43
20-83-920-66-76
30-124-1330-99-109
40-166-1740-132-142
50-207-2150-165-175
60-248-2560-198-208
70-290-2970-231-241
80-331-3380-264-274
90-373-3790-297-307
100-414-4200-331-340

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%3.09.00.025.0%4.016.00.020.0%7.033.00.017.5%19.041.00.031.7%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%11.029.00.027.5%23.034.03.038.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.060.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%11.029.00.027.5%23.034.03.038.3%

Fundamentals of Morphosys

About Morphosys AG O.N.

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Fundamental data was last updated by Penke on 2024-05-01 18:46:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Morphosys AG O.N..

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Morphosys earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Morphosys to the Biotechnology industry mean.
  • A Net Profit Margin of 81.7% means that €0.82 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Morphosys AG O.N.:

  • The MRQ is 81.7%. The company is making a huge profit. +2
  • The TTM is -78.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ81.7%TTM-78.8%+160.5%
TTM-78.8%YOY-136.9%+58.1%
TTM-78.8%5Y-163.6%+84.8%
5Y-163.6%10Y-143.7%-19.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ81.7%-174.3%+256.0%
TTM-78.8%-210.4%+131.6%
YOY-136.9%-266.3%+129.4%
5Y-163.6%-408.9%+245.3%
10Y-143.7%-552.3%+408.6%
1.1.2. Return on Assets

Shows how efficient Morphosys is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Morphosys to the Biotechnology industry mean.
  • 2.4% Return on Assets means that Morphosys generated €0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Morphosys AG O.N.:

  • The MRQ is 2.4%. Using its assets, the company is less efficient in making profit.
  • The TTM is -2.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ2.4%TTM-2.2%+4.6%
TTM-2.2%YOY-1.8%-0.4%
TTM-2.2%5Y-2.5%+0.3%
5Y-2.5%10Y-2.3%-0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4%-11.9%+14.3%
TTM-2.2%-11.6%+9.4%
YOY-1.8%-11.0%+9.2%
5Y-2.5%-13.1%+10.6%
10Y-2.3%-14.4%+12.1%
1.1.3. Return on Equity

Shows how efficient Morphosys is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Morphosys to the Biotechnology industry mean.
  • 98.4% Return on Equity means Morphosys generated €0.98 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Morphosys AG O.N.:

  • The MRQ is 98.4%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is -45.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ98.4%TTM-45.1%+143.5%
TTM-45.1%YOY21.1%-66.1%
TTM-45.1%5Y-14.5%-30.6%
5Y-14.5%10Y-8.4%-6.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ98.4%-15.3%+113.7%
TTM-45.1%-14.7%-30.4%
YOY21.1%-13.6%+34.7%
5Y-14.5%-17.7%+3.2%
10Y-8.4%-19.2%+10.8%

1.2. Operating Efficiency of Morphosys AG O.N..

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Morphosys is operating .

  • Measures how much profit Morphosys makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Morphosys to the Biotechnology industry mean.
  • An Operating Margin of -137.7% means the company generated €-1.38  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Morphosys AG O.N.:

  • The MRQ is -137.7%. The company is operating very inefficient. -2
  • The TTM is -102.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-137.7%TTM-102.9%-34.8%
TTM-102.9%YOY-84.3%-18.6%
TTM-102.9%5Y-145.6%+42.7%
5Y-145.6%10Y-136.6%-9.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-137.7%-332.1%+194.4%
TTM-102.9%-220.9%+118.0%
YOY-84.3%-281.8%+197.5%
5Y-145.6%-408.0%+262.4%
10Y-136.6%-521.7%+385.1%
1.2.2. Operating Ratio

Measures how efficient Morphosys is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.38 means that the operating costs are €2.38 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Morphosys AG O.N.:

  • The MRQ is 2.375. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.054. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.375TTM2.054+0.321
TTM2.054YOY1.926+0.127
TTM2.0545Y2.482-0.428
5Y2.48210Y2.392+0.090
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3753.003-0.628
TTM2.0543.246-1.192
YOY1.9263.619-1.693
5Y2.4825.190-2.708
10Y2.3926.874-4.482

1.3. Liquidity of Morphosys AG O.N..

1.3. Liquidity
1.3.1. Current Ratio

Measures if Morphosys is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.08 means the company has €3.08 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Morphosys AG O.N.:

  • The MRQ is 3.080. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.347. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.080TTM3.347-0.267
TTM3.347YOY3.723-0.377
TTM3.3475Y5.351-2.005
5Y5.35110Y7.124-1.773
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0803.814-0.734
TTM3.3474.158-0.811
YOY3.7235.253-1.530
5Y5.3516.098-0.747
10Y7.1246.434+0.690
1.3.2. Quick Ratio

Measures if Morphosys is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Morphosys to the Biotechnology industry mean.
  • A Quick Ratio of 4.73 means the company can pay off €4.73 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Morphosys AG O.N.:

  • The MRQ is 4.728. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.901. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.728TTM4.901-0.173
TTM4.901YOY5.603-0.703
TTM4.9015Y8.717-3.816
5Y8.71710Y10.614-1.896
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.7283.246+1.482
TTM4.9013.837+1.064
YOY5.6035.195+0.408
5Y8.7175.929+2.788
10Y10.6146.351+4.263

1.4. Solvency of Morphosys AG O.N..

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Morphosys assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Morphosys to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.98 means that Morphosys assets are financed with 97.6% credit (debt) and the remaining percentage (100% - 97.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Morphosys AG O.N.:

  • The MRQ is 0.976. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.987. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.976TTM0.987-0.012
TTM0.987YOY0.979+0.008
TTM0.9875Y0.689+0.298
5Y0.68910Y0.407+0.282
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9760.344+0.632
TTM0.9870.342+0.645
YOY0.9790.279+0.700
5Y0.6890.366+0.323
10Y0.4070.380+0.027
1.4.2. Debt to Equity Ratio

Measures if Morphosys is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Morphosys to the Biotechnology industry mean.
  • A Debt to Equity ratio of 4,031.2% means that company has €40.31 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Morphosys AG O.N.:

  • The MRQ is 40.312. The company is unable to pay all its debts with equity. -1
  • The TTM is 32.236. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ40.312TTM32.236+8.076
TTM32.236YOY7.641+24.594
TTM32.2365Y9.113+23.122
5Y9.11310Y4.630+4.484
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ40.3120.398+39.914
TTM32.2360.415+31.821
YOY7.6410.353+7.288
5Y9.1130.446+8.667
10Y4.6300.469+4.161

2. Market Valuation of Morphosys AG O.N.

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Morphosys generates.

  • Above 15 is considered overpriced but always compare Morphosys to the Biotechnology industry mean.
  • A PE ratio of 6.97 means the investor is paying €6.97 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Morphosys AG O.N.:

  • The EOD is 14.027. Based on the earnings, the company is underpriced. +1
  • The MRQ is 6.967. Based on the earnings, the company is cheap. +2
  • The TTM is -0.412. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD14.027MRQ6.967+7.059
MRQ6.967TTM-0.412+7.379
TTM-0.412YOY-0.964+0.552
TTM-0.4125Y-15.772+15.360
5Y-15.77210Y-63.723+47.952
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD14.027-2.359+16.386
MRQ6.967-2.548+9.515
TTM-0.412-2.742+2.330
YOY-0.964-3.936+2.972
5Y-15.772-6.316-9.456
10Y-63.723-6.544-57.179
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Morphosys AG O.N.:

  • The EOD is -11.868. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.895. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.188. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-11.868MRQ-5.895-5.973
MRQ-5.895TTM-4.188-1.707
TTM-4.188YOY-3.348-0.840
TTM-4.1885Y49.598-53.786
5Y49.59810Y-14.001+63.599
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-11.868-3.091-8.777
MRQ-5.895-3.283-2.612
TTM-4.188-3.529-0.659
YOY-3.348-5.188+1.840
5Y49.598-8.080+57.678
10Y-14.001-8.660-5.341
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Morphosys is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 27.42 means the investor is paying €27.42 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Morphosys AG O.N.:

  • The EOD is 55.210. Based on the equity, the company is expensive. -2
  • The MRQ is 27.424. Based on the equity, the company is expensive. -2
  • The TTM is 12.750. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD55.210MRQ27.424+27.787
MRQ27.424TTM12.750+14.674
TTM12.750YOY-6.259+19.008
TTM12.7505Y5.043+7.707
5Y5.04310Y5.766-0.723
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD55.2102.094+53.116
MRQ27.4242.032+25.392
TTM12.7502.065+10.685
YOY-6.2592.688-8.947
5Y5.0433.692+1.351
10Y5.7664.085+1.681
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Morphosys AG O.N. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--3.015-0.733+124%-0.580+119%-0.585+119%-0.202+107%
Book Value Per Share--1.2400.719+72%1.230+1%8.788-86%9.515-87%
Current Ratio--3.0803.347-8%3.723-17%5.351-42%7.124-57%
Debt To Asset Ratio--0.9760.987-1%0.9790%0.689+42%0.407+140%
Debt To Equity Ratio--40.31232.236+25%7.641+428%9.113+342%4.630+771%
Dividend Per Share----0%-0%-0%-0%
Eps--1.220-1.273+204%-1.001+182%-1.144+194%-0.687+156%
Free Cash Flow Per Share---1.442-1.905+32%-2.490+73%-1.682+17%-0.976-32%
Free Cash Flow To Equity Per Share--0.960-1.648+272%-0.415+143%1.742-45%1.050-9%
Gross Profit Margin---0.0870.940-109%1.056-108%1.187-107%1.097-108%
Intrinsic Value_10Y_max--7.260--------
Intrinsic Value_10Y_min---93.267--------
Intrinsic Value_1Y_max---3.238--------
Intrinsic Value_1Y_min---10.242--------
Intrinsic Value_3Y_max---6.707--------
Intrinsic Value_3Y_min---30.179--------
Intrinsic Value_5Y_max---6.532--------
Intrinsic Value_5Y_min---49.313--------
Market Cap2581687580.000+48%1345105348.000974673552.500+38%728916575.500+85%2249582746.000-40%2379285982.500-43%
Net Profit Margin--0.817-0.788+196%-1.369+268%-1.636+300%-1.437+276%
Operating Margin---1.377-1.029-25%-0.843-39%-1.456+6%-1.366-1%
Operating Ratio--2.3752.054+16%1.926+23%2.482-4%2.392-1%
Pb Ratio55.210+50%27.42412.750+115%-6.259+123%5.043+444%5.766+376%
Pe Ratio14.027+50%6.967-0.412+106%-0.964+114%-15.772+326%-63.723+1015%
Price Per Share68.450+50%34.00025.426+34%19.326+76%59.562-43%63.042-46%
Price To Free Cash Flow Ratio-11.868-101%-5.895-4.188-29%-3.348-43%49.598-112%-14.001+138%
Price To Total Gains Ratio22.701+50%11.276-5.866+152%-6.101+154%-100.759+994%-59.148+625%
Quick Ratio--4.7284.901-4%5.603-16%8.717-46%10.614-55%
Return On Assets--0.024-0.022+192%-0.018+175%-0.025+206%-0.023+195%
Return On Equity--0.984-0.451+146%0.211+367%-0.145+115%-0.084+109%
Total Gains Per Share--3.015-0.733+124%-0.580+119%-0.585+119%-0.202+107%
Usd Book Value--53257663.70630071108.576+77%50359818.233+6%360010158.040-85%389715341.212-86%
Usd Book Value Change Per Share--3.274-0.796+124%-0.630+119%-0.636+119%-0.220+107%
Usd Book Value Per Share--1.3460.781+72%1.335+1%9.542-86%10.331-87%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--1.325-1.382+204%-1.087+182%-1.242+194%-0.746+156%
Usd Free Cash Flow---61938823.635-78749366.264+27%-101966828.692+65%-69014332.601+11%-40040267.457-35%
Usd Free Cash Flow Per Share---1.566-2.069+32%-2.704+73%-1.826+17%-1.060-32%
Usd Free Cash Flow To Equity Per Share--1.043-1.789+272%-0.451+143%1.891-45%1.140-9%
Usd Market Cap2803196374.364+48%1460515386.8581058300543.305+38%791457617.678+85%2442596945.607-40%2583428719.799-43%
Usd Price Per Share74.323+50%36.91727.608+34%20.984+76%64.672-43%68.451-46%
Usd Profit--52407006.726-51355082.057+198%-55850539.176+207%-51622061.547+199%-30547649.420+158%
Usd Revenue--64147232.25564703307.081-1%75546876.528-15%59487508.797+8%39602214.015+62%
Usd Total Gains Per Share--3.274-0.796+124%-0.630+119%-0.636+119%-0.220+107%
 EOD+5 -3MRQTTM+24 -10YOY+24 -105Y+19 -1510Y+14 -20

3.2. Fundamental Score

Let's check the fundamental score of Morphosys AG O.N. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1514.027
Price to Book Ratio (EOD)Between0-155.210
Net Profit Margin (MRQ)Greater than00.817
Operating Margin (MRQ)Greater than0-1.377
Quick Ratio (MRQ)Greater than14.728
Current Ratio (MRQ)Greater than13.080
Debt to Asset Ratio (MRQ)Less than10.976
Debt to Equity Ratio (MRQ)Less than140.312
Return on Equity (MRQ)Greater than0.150.984
Return on Assets (MRQ)Greater than0.050.024
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Morphosys AG O.N. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.376
Ma 20Greater thanMa 5067.410
Ma 50Greater thanMa 10067.146
Ma 100Greater thanMa 20058.480
OpenGreater thanClose68.100
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets2,026,311
Total Liabilities1,977,262
Total Stockholder Equity49,049
 As reported
Total Liabilities 1,977,262
Total Stockholder Equity+ 49,049
Total Assets = 2,026,311

Assets

Total Assets2,026,311
Total Current Assets814,022
Long-term Assets1,212,290
Total Current Assets
Cash And Cash Equivalents 158,500
Short-term Investments 524,256
Net Receivables 42,655
Inventory 62,068
Other Current Assets 0
Total Current Assets  (as reported)814,022
Total Current Assets  (calculated)787,479
+/- 26,543
Long-term Assets
Property Plant Equipment 14,991
Goodwill 342,297
Long Term Investments 3,552
Intangible Assets 844,109
Long-term Assets Other 1,217
Long-term Assets  (as reported)1,212,290
Long-term Assets  (calculated)1,206,166
+/- 6,124

Liabilities & Shareholders' Equity

Total Current Liabilities264,311
Long-term Liabilities1,712,951
Total Stockholder Equity49,049
Total Current Liabilities
Short-term Debt 14,051
Short Long Term Debt 10,422
Accounts payable 28,388
Other Current Liabilities 202,429
Total Current Liabilities  (as reported)264,311
Total Current Liabilities  (calculated)255,289
+/- 9,022
Long-term Liabilities
Long term Debt 613,085
Capital Lease Obligations 12,425
Long-term Liabilities Other 1,056,157
Long-term Liabilities  (as reported)1,712,951
Long-term Liabilities  (calculated)1,681,667
+/- 31,284
Total Stockholder Equity
Common Stock37,655
Retained Earnings -1,013,134
Accumulated Other Comprehensive Income 88,435
Other Stockholders Equity 936,093
Total Stockholder Equity (as reported)49,049
Total Stockholder Equity (calculated)49,049
+/-0
Other
Capital Stock37,655
Cash and Short Term Investments 682,756
Common Stock Shares Outstanding 39,562
Current Deferred Revenue19,444
Liabilities and Stockholders Equity 2,026,311
Net Debt 477,432
Net Invested Capital 672,556
Net Working Capital 549,711
Property Plant and Equipment Gross 37,714
Short Long Term Debt Total 635,932



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-31
> Total Assets 
0
0
0
206,091
211,054
226,549
210,471
212,554
246,695
238,614
239,667
228,410
227,634
223,861
224,911
224,289
232,838
246,389
456,416
447,657
436,929
434,214
434,076
426,478
431,239
429,375
422,464
400,079
391,549
380,598
374,617
463,600
453,892
451,043
420,293
415,398
392,152
547,759
578,704
538,764
556,305
556,791
541,145
496,439
1,335,339
1,424,105
1,380,148
1,659,513
1,649,905
1,577,414
2,883,944
2,556,254
2,457,357
2,508,517
2,848,973
2,396,932
2,229,510
2,142,502
2,100,982
2,026,311
2,026,3112,100,9822,142,5022,229,5102,396,9322,848,9732,508,5172,457,3572,556,2542,883,9441,577,4141,649,9051,659,5131,380,1481,424,1051,335,339496,439541,145556,791556,305538,764578,704547,759392,152415,398420,293451,043453,892463,600374,617380,598391,549400,079422,464429,375431,239426,478434,076434,214436,929447,657456,416246,389232,838224,289224,911223,861227,634228,410239,667238,614246,695212,554210,471226,549211,054206,091000
   > Total Current Assets 
0
0
0
155,592
160,982
166,489
151,123
132,506
167,692
160,970
162,931
154,693
154,754
152,147
154,129
183,714
188,169
199,600
414,791
406,568
369,884
368,633
381,549
322,395
314,510
328,738
320,205
300,116
286,486
242,612
238,439
308,056
303,229
289,942
274,704
340,681
318,052
397,612
456,410
388,905
367,017
393,993
419,765
303,693
1,079,185
927,927
858,435
1,206,816
1,257,376
1,255,907
1,294,759
1,132,970
1,013,436
948,810
1,238,942
1,089,041
949,576
862,874
797,978
814,022
814,022797,978862,874949,5761,089,0411,238,942948,8101,013,4361,132,9701,294,7591,255,9071,257,3761,206,816858,435927,9271,079,185303,693419,765393,993367,017388,905456,410397,612318,052340,681274,704289,942303,229308,056238,439242,612286,486300,116320,205328,738314,510322,395381,549368,633369,884406,568414,791199,600188,169183,714154,129152,147154,754154,693162,931160,970167,692132,506151,123166,489160,982155,592000
       Cash And Cash Equivalents 
0
0
0
41,255
45,349
43,461
41,221
44,118
50,555
59,166
64,492
54,596
38,282
43,731
48,889
41,674
39,827
48,685
104,922
72,838
47,250
51,646
74,009
32,811
33,674
55,668
26,623
91,559
131,821
67,584
30,075
75,181
116,508
61,995
88,768
77,722
57,418
55,538
120,974
45,460
48,520
54,705
58,541
44,314
620,820
33,404
64,313
109,795
109,586
297,335
249,767
123,248
108,873
119,054
457,140
402,351
291,748
184,328
187,836
158,500
158,500187,836184,328291,748402,351457,140119,054108,873123,248249,767297,335109,586109,79564,31333,404620,82044,31458,54154,70548,52045,460120,97455,53857,41877,72288,76861,995116,50875,18130,07567,584131,82191,55926,62355,66833,67432,81174,00951,64647,25072,838104,92248,68539,82741,67448,88943,73138,28254,59664,49259,16650,55544,11841,22143,46145,34941,255000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
78,616
79,722
122,570
97,617
197,239
199,462
204,817
197,340
98,383
113,528
101,977
94,454
110,699
97,413
91,210
93,176
117,951
69,894
70,759
75,248
78,140
86,538
228,342
316,065
309,042
313,504
286,874
284,715
328,916
228,190
419,641
826,722
725,186
980,522
1,012,670
798,010
905,426
870,417
746,597
607,772
587,340
504,823
499,732
487,445
453,212
524,256
524,256453,212487,445499,732504,823587,340607,772746,597870,417905,426798,0101,012,670980,522725,186826,722419,641228,190328,916284,715286,874313,504309,042316,065228,34286,53878,14075,24870,75969,894117,95193,17691,21097,413110,69994,454101,977113,52898,383197,340204,817199,462197,23997,617122,57079,72278,61600000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19,332
23,559
50,547
109,544
129,806
113,909
114,961
206,118
173,204
174,448
175,216
178,783
108,180
56,901
76,756
79,960
149,882
99,672
136,950
93,360
163,433
13,170
12,673
14,511
20,741
21,365
43,221
23,385
20,341
27,844
36,658
39,926
89,836
104,173
108,192
82,068
85,790
80,049
135,251
108,108
112,354
78,059
86,184
58,355
42,655
42,65558,35586,18478,059112,354108,108135,25180,04985,79082,068108,192104,17389,83639,92636,65827,84420,34123,38543,22121,36520,74114,51112,67313,170163,43393,360136,95099,672149,88279,96076,75656,901108,180178,783175,216174,448173,204206,118114,961113,909129,806109,54450,54723,55919,332000000000000000
       Other Current Assets 
0
0
0
110,346
111,912
119,087
106,149
84,253
113,182
98,183
94,882
96,815
113,239
104,922
22,930
42,229
1,461
2,010
2,309
3,730
3,152
3,953
2,494
2,296
3,864
2,873
3,571
2,596
6,172
4,728
10,112
12,789
15,973
15,397
14,131
12,687
18,821
13,060
11,619
8,955
10,017
11,035
8,642
10,560
10,488
15,813
13,772
16,701
17,546
37,853
44,228
32,760
57,026
63,304
0
0
44,761
33,188
28,043
0
028,04333,18844,7610063,30457,02632,76044,22837,85317,54616,70113,77215,81310,48810,5608,64211,03510,0178,95511,61913,06018,82112,68714,13115,39715,97312,78910,1124,7286,1722,5963,5712,8733,8642,2962,4943,9533,1523,7302,3092,0101,46142,22922,930104,922113,23996,81594,88298,183113,18284,253106,149119,087111,912110,346000
   > Long-term Assets 
0
0
0
50,499
50,073
60,061
59,347
80,047
79,003
77,644
76,736
73,718
72,880
71,714
70,782
40,575
44,668
46,789
41,625
41,089
67,046
65,580
52,526
104,083
116,729
100,637
102,259
99,963
105,064
137,987
136,178
155,544
150,663
161,101
145,589
74,718
74,100
150,146
122,294
149,858
189,289
162,798
121,380
192,746
256,155
496,178
521,713
452,697
392,529
321,507
1,589,185
1,423,284
1,443,921
1,559,707
0
1,307,891
1,279,934
1,279,628
1,303,004
1,212,290
1,212,2901,303,0041,279,6281,279,9341,307,89101,559,7071,443,9211,423,2841,589,185321,507392,529452,697521,713496,178256,155192,746121,380162,798189,289149,858122,294150,14674,10074,718145,589161,101150,663155,544136,178137,987105,06499,963102,259100,637116,729104,08352,52665,58067,04641,08941,62546,78944,66840,57570,78271,71472,88073,71876,73677,64479,00380,04759,34760,06150,07350,499000
       Property Plant Equipment 
0
0
0
4,997
5,151
5,045
4,985
6,190
6,344
6,389
6,305
6,106
6,093
5,628
5,287
3,192
3,005
2,911
2,735
2,168
3,027
3,009
3,390
3,558
3,498
3,582
3,557
3,474
3,334
2,975
3,114
4,189
4,147
3,983
3,766
3,526
3,429
3,172
2,936
3,531
45,259
45,032
48,743
4,696
52,423
51,570
52,111
50,742
49,922
49,424
51,916
49,592
48,648
50,083
48,956
50,988
49,372
47,552
45,346
14,991
14,99145,34647,55249,37250,98848,95650,08348,64849,59251,91649,42449,92250,74252,11151,57052,4234,69648,74345,03245,2593,5312,9363,1723,4293,5263,7663,9834,1474,1893,1142,9753,3343,4743,5573,5823,4983,5583,3903,0093,0272,1682,7352,9113,0053,1925,2875,6286,0936,1066,3056,3896,3446,1904,9855,0455,1514,997000
       Goodwill 
0
0
0
26,742
26,706
26,751
26,762
34,099
34,107
34,100
34,091
34,107
34,124
34,130
0
7,353
7,352
7,352
7,352
7,352
7,352
7,352
7,352
7,352
7,352
11,041
11,041
7,365
7,365
7,365
7,365
7,365
7,365
7,365
7,365
7,365
7,365
7,365
7,365
3,676
3,676
3,676
3,676
3,676
3,676
3,676
3,676
1,619
1,619
1,619
570,959
335,574
342,343
365,766
389,637
356,240
349,424
349,712
357,030
342,297
342,297357,030349,712349,424356,240389,637365,766342,343335,574570,9591,6191,6191,6193,6763,6763,6763,6763,6763,6763,6763,6767,3657,3657,3657,3657,3657,3657,3657,3657,3657,3657,3657,36511,04111,0417,3527,3527,3527,3527,3527,3527,3527,3527,3527,353034,13034,12434,10734,09134,10034,10734,09926,76226,75126,70626,742000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
79,521
75,014
75,027
70,029
0
0
78,912
51,557
95,981
232
338
338
14,077
10,815
9,408
254,840
196,588
125,713
55,378
0
0
0
39,420
0
5,352
2,860
4,074
0
3,552
3,55204,0742,8605,352039,42000055,378125,713196,588254,8409,40810,81514,07733833823295,98151,55778,9120070,02975,02775,01479,5210000000000000000000000000000000
       Intangible Assets 
0
0
0
17,366
16,835
26,721
26,024
35,109
34,005
33,338
32,566
31,921
31,062
30,282
0
27,659
27,276
29,469
27,993
27,797
27,191
26,745
37,936
38,627
43,049
70,957
72,616
72,282
71,884
71,480
71,072
60,574
60,202
70,966
60,769
60,482
60,041
57,544
57,353
43,689
43,375
43,128
42,839
41,122
52,272
38,256
58,773
69,376
69,045
79,025
787,906
838,322
853,209
908,026
965,353
886,583
870,034
870,318
891,138
844,109
844,109891,138870,318870,034886,583965,353908,026853,209838,322787,90679,02569,04569,37658,77338,25652,27241,12242,83943,12843,37543,68957,35357,54460,04160,48260,76970,96660,20260,57471,07271,48071,88472,28272,61670,95743,04938,62737,93626,74527,19127,79727,99329,46927,27627,659030,28231,06231,92132,56633,33834,00535,10926,02426,72116,83517,366000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,894
3,936
3,761
3,660
3,344
3,265
3,153
3,083
2,982
934
891
827
1,136
1,127
146,217
152,313
134,373
146,230
136,061
178,404
199,796
199,721
196,413
196,900
8,729
8,245
7,972
0
0
007,9728,2458,729196,900196,413199,721199,796178,404136,061146,230134,373152,313146,2171,1271,1368278919342,9823,0833,1533,2653,3443,6603,7613,9363,8940000000000000000000000000000000
> Total Liabilities 
0
0
0
32,156
33,192
45,101
27,376
26,632
40,910
36,746
39,506
31,275
30,004
26,671
26,808
22,279
20,607
24,120
103,158
95,511
90,632
84,648
86,232
77,675
40,883
47,075
47,601
37,343
38,266
38,055
44,628
48,140
52,309
58,798
50,391
56,727
51,541
48,851
47,481
50,391
89,929
93,749
98,078
101,738
666,645
767,593
782,109
1,038,191
1,070,253
976,007
2,286,694
2,311,378
2,315,619
2,535,976
2,935,141
2,239,523
2,132,483
2,110,833
2,167,948
1,977,262
1,977,2622,167,9482,110,8332,132,4832,239,5232,935,1412,535,9762,315,6192,311,3782,286,694976,0071,070,2531,038,191782,109767,593666,645101,73898,07893,74989,92950,39147,48148,85151,54156,72750,39158,79852,30948,14044,62838,05538,26637,34347,60147,07540,88377,67586,23284,64890,63295,511103,15824,12020,60722,27926,80826,67130,00431,27539,50636,74640,91026,63227,37645,10133,19232,156000
   > Total Current Liabilities 
0
0
0
24,252
26,504
42,086
24,589
21,351
30,271
26,783
29,398
23,751
22,692
19,442
20,005
15,650
14,217
18,149
39,510
35,407
33,757
31,248
36,541
32,703
36,294
35,790
36,360
27,470
28,673
28,863
34,994
38,302
42,109
49,039
40,951
47,701
42,667
41,171
39,652
45,923
47,380
51,740
53,846
61,558
83,849
171,619
170,875
200,459
202,263
204,554
259,123
284,538
238,959
317,916
329,894
278,347
263,897
241,701
254,221
264,311
264,311254,221241,701263,897278,347329,894317,916238,959284,538259,123204,554202,263200,459170,875171,61983,84961,55853,84651,74047,38045,92339,65241,17142,66747,70140,95149,03942,10938,30234,99428,86328,67327,47036,36035,79036,29432,70336,54131,24833,75735,40739,51018,14914,21715,65020,00519,44222,69223,75129,39826,78330,27121,35124,58942,08626,50424,252000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
78,616
79,722
122,570
97,617
197,239
199,462
204,817
197,340
98,383
113,528
101,977
94,454
110,699
97,413
91,210
93,176
117,951
69,894
70,759
75,248
78,140
86,538
228,342
316,065
309,042
313,504
2,017
2,112
2,643
2,527
3,026
3,120
3,148
3,479
4,029
3,682
4,092
3,661
5,310
5,536
0
9,592
6,022
5,177
4,784
14,051
14,0514,7845,1776,0229,59205,5365,3103,6614,0923,6824,0293,4793,1483,1203,0262,5272,6432,1122,017313,504309,042316,065228,34286,53878,14075,24870,75969,894117,95193,17691,21097,413110,69994,454101,977113,52898,383197,340204,817199,462197,23997,617122,57079,72278,61600000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
218
218
135
125
88
88
87
0
0
2,017
72
27
12
0
0
0
423
924
417
929
423
2,031
2,031
0
2,031
1,637
1,640
0
10,422
10,42201,6401,6372,03102,0312,0314239294179244230001227722,017008788881251352182180000000000000000000000000000000
       Accounts payable 
0
0
0
14,106
10,006
11,264
12,260
15,615
13,424
16,230
17,000
19,111
15,557
15,850
14,166
738
8,651
11,306
16,298
1,078
12,100
0
0
569
0
25,048
0
237
19,687
22,419
25,911
8,457
32,512
43,979
34,045
4,622
40,549
40,012
38,480
7,215
43,666
48,801
50,130
10,655
52,217
54,139
74,431
47,559
124,297
134,663
168,399
73,787
145,550
158,464
196,622
38,579
149,225
119,819
116,961
28,388
28,388116,961119,819149,22538,579196,622158,464145,55073,787168,399134,663124,29747,55974,43154,13952,21710,65550,13048,80143,6667,21538,48040,01240,5494,62234,04543,97932,5128,45725,91122,41919,687237025,04805690012,1001,07816,29811,3068,65173814,16615,85015,55719,11117,00016,23013,42415,61512,26011,26410,00614,106000
       Other Current Liabilities 
0
0
0
10,146
16,498
30,822
12,330
5,736
16,846
10,553
12,399
4,640
7,135
3,592
5,839
14,284
1,639
5,694
3,789
19,062
2,994
16,374
18,937
18,059
31,439
9,581
32,195
25,239
3,675
3,980
4,377
28,613
3,782
2,812
1,778
41,690
1,587
729
39,045
37,914
410
49,079
50,379
46,805
72,128
163,505
163,650
146,878
193,687
200,090
254,767
206,866
230,975
276,839
127,634
230,175
108,650
111,991
131,214
202,429
202,429131,214111,991108,650230,175127,634276,839230,975206,866254,767200,090193,687146,878163,650163,50572,12846,80550,37949,07941037,91439,0457291,58741,6901,7782,8123,78228,6134,3773,9803,67525,23932,1959,58131,43918,05918,93716,3742,99419,0623,7895,6941,63914,2845,8393,5927,1354,64012,39910,55316,8465,73612,33030,82216,49810,146000
   > Long-term Liabilities 
0
0
0
7,904
6,688
3,015
2,787
5,281
10,640
9,963
10,107
7,524
7,312
7,228
6,803
6,628
6,390
5,971
63,649
60,104
56,875
53,400
49,691
44,972
4,589
11,285
11,240
9,873
9,593
9,192
9,634
9,838
10,200
9,759
9,440
9,026
8,874
7,680
7,829
4,468
42,549
42,009
44,232
40,180
582,796
595,973
611,234
837,732
867,990
771,454
2,027,571
2,026,840
2,076,660
2,218,060
0
1,961,176
1,868,586
1,869,132
1,913,728
1,712,951
1,712,9511,913,7281,869,1321,868,5861,961,17602,218,0602,076,6602,026,8402,027,571771,454867,990837,732611,234595,973582,79640,18044,23242,00942,5494,4687,8297,6808,8749,0269,4409,75910,2009,8389,6349,1929,5939,87311,24011,2854,58944,97249,69153,40056,87560,10463,6495,9716,3906,6286,8037,2287,3127,52410,1079,96310,6405,2812,7873,0156,6887,904000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
38,336
37,765
40,693
40,042
44,828
43,991
43,004
314,724
316,630
318,270
320,184
322,130
322,835
326,404
328,974
329,867
275,059
275,943
0
0
00275,943275,059329,867328,974326,404322,835322,130320,184318,270316,630314,72443,00443,99144,82840,04240,69337,76538,3360000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,620
9,981
9,624
9,315
8,938
8,786
7,593
7,758
4,396
4,213
4,244
3,539
138
537,968
551,982
568,231
523,008
551,360
453,183
1,707,387
1,704,710
1,753,824
1,891,655
2,276,273
1,631,310
0
1,593,189
0
0
001,593,18901,631,3102,276,2731,891,6551,753,8241,704,7101,707,387453,183551,360523,008568,231551,982537,9681383,5394,2444,2134,3967,7587,5938,7868,9389,3159,6249,9819,6200000000000000000000000000000000
> Total Stockholder Equity
0
0
0
173,934
177,862
181,449
183,095
185,922
205,785
201,868
200,161
197,136
197,630
197,190
198,103
202,010
212,231
222,269
353,258
352,145
346,297
349,566
347,843
348,803
390,356
382,301
374,863
362,736
353,284
342,544
329,989
415,460
401,584
392,245
369,902
358,671
340,612
498,908
531,223
488,373
466,376
463,042
443,067
394,702
668,695
656,513
598,038
621,322
579,653
601,407
597,250
244,876
141,739
-27,459
-86,168
157,410
97,027
31,669
-66,966
49,049
49,049-66,96631,66997,027157,410-86,168-27,459141,739244,876597,250601,407579,653621,322598,038656,513668,695394,702443,067463,042466,376488,373531,223498,908340,612358,671369,902392,245401,584415,460329,989342,544353,284362,736374,863382,301390,356348,803347,843349,566346,297352,145353,258222,269212,231202,010198,103197,190197,630197,136200,161201,868205,785185,922183,095181,449177,862173,934000
   Common Stock
0
0
0
161,631
22,667
22,667
22,784
22,880
22,928
23,035
23,048
23,112
23,155
23,253
23,309
23,358
23,358
23,401
26,111
26,221
26,221
26,373
26,392
26,457
26,463
26,470
26,479
26,538
26,538
26,538
26,538
29,160
29,160
29,326
29,346
29,421
29,421
31,808
31,840
31,840
31,840
31,840
31,928
31,958
32,890
32,890
32,890
32,890
32,890
32,893
34,232
34,232
34,232
34,232
34,232
34,232
34,232
34,232
34,232
37,655
37,65534,23234,23234,23234,23234,23234,23234,23234,23234,23232,89332,89032,89032,89032,89032,89031,95831,92831,84031,84031,84031,84031,80829,42129,42129,34629,32629,16029,16026,53826,53826,53826,53826,47926,47026,46326,45726,39226,37326,22126,22126,11123,40123,35823,35823,30923,25323,15523,11223,04823,03522,92822,88022,78422,66722,667161,631000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-9,753
0
0
0
-11,590
0
0
0
-12,806
0
0
0
-623
681
377
401
433
549
667
253
289
309
354
255
-202
-745
-716
-1,069
136
62
-354
-103
-105
0
0
-52
-211
-225
-73
-505
-1,296
-5,307
-4,281
599
2,211
1,284
1,617
25,181
52,758
72,216
137,396
0
115,327
98,541
99,374
118,838
88,435
88,435118,83899,37498,541115,3270137,39672,21652,75825,1811,6171,2842,211599-4,281-5,307-1,296-505-73-225-211-5200-105-103-35462136-1,069-716-745-202255354309289253667549433401377681-623000-12,806000-11,590000-9,753000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
620,567
622,013
626,342
628,177
709,737
710,306
711,496
748,979
749,846
749,284
832,584
833,321
833,376
833,820
834,488
833,709
834,543
842,166
0
0
00842,166834,543833,709834,488833,820833,376833,321832,584749,284749,846748,979711,496710,306709,737628,177626,342622,013620,5670000000000000000000000000000000000000000
   Treasury Stock00000000-3,085-3,372-3,783-4,869-4,869-5,582-6,384-8,357-8,357-9,247-9,443-10,3700000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
24,034
163,734
164,648
164,824
165,576
166,562
166,359
166,635
168,342
169,319
169,230
170,335
171,651
172,712
171,900
302,261
304,546
297,491
301,017
302,261
304,124
304,796
301,023
301,964
303,566
301,864
302,712
303,327
413,713
414,952
421,938
423,345
426,731
427,273
606,720
608,836
609,510
610,197
612,570
617,095
619,819
701,380
703,923
705,913
744,110
744,977
745,501
829,212
830,236
830,291
830,905
200,614
831,258
832,093
839,869
841,371
936,093
936,093841,371839,869832,093831,258200,614830,905830,291830,236829,212745,501744,977744,110705,913703,923701,380619,819617,095612,570610,197609,510608,836606,720427,273426,731423,345421,938414,952413,713303,327302,712301,864303,566301,964301,023304,796304,124302,261301,017297,491304,546302,261171,900172,712171,651170,335169,230169,319168,342166,635166,359166,562165,576164,824164,648163,73424,034000



Balance Sheet

Currency in EUR. All numbers in thousands.